Explore Stanford technologies available for licensing:

Stanford researchers have developed an innovative AI-driven solution for predicting immunotherapy response in esophagogastric cancer patients.

Engineering novel proteins through directed evolution have become a foundation of protein engineering in biotech. However, these techniques are incapable of simultaneous engineering of protein-protein pairs through library-on-library selections.

Researchers at Stanford University have developed a novel platform for genetically engineering cells within a living organism, circumventing previous limitations related to accessing target tissues and the size of the genetic payload.

Researchers at Stanford have developed methods for preparing chromatin from cells for downstream genomic chromatin mapping.

Stanford researchers have developed a new gene editing approach that enables red blood cell-specific gene expression for the treatment of enzyme deficiencies.

The coronavirus main protease (Mpro), which is a trypsin-like protease with a catalytic cysteine residue, processes viral proteins in an early step of the coronavirus life cycle, and its activity is required for viral replication.

Researchers at Stanford have combined 3D printing and pyrolysis to produce a robust and biocompatible high resolution micro-array patch (MAP) for transdermal drug delivery.

Researchers at Stanford have developed engineered IL-2 "surrogate" mutant agonists with varying patterns of STAT1/3/5, ERK, and PI3K signaling, as well as preferential induction of memory T cell differentiation and NK cell cytotoxicity relative to native IL-2.

Scientists in Sergiu Pasca's group at Stanford University have used patient-derived organoids, assembloids and in vivo transplantation to discover and validate an antisense oligonucleotide drug for the treatment of Timothy syndrome.

Stanford researchers have engineered chimeric cytokine receptors that are expressed in therapeutic cells to enhance their activity and therapeutic potential.

There is broad potential to modulate RNA using small molecules, replacing more costly and difficult-to-administer oligonucleotide therapies. However, methods for screening for such small molecules are lacking.

Stanford researchers have developed a scalable assay that combines single-molecule nucleic acid imaging with single-cell sequencing, enabling the enrichment and detailed study of rare cell populations in complex biological samples.

Stem cells are generally influenced by a microenvironmental niche, typically comprised of epithelial and mesenchymal cells and extracellular substrates. Many attempts have been made to produce culture systems that mimic normal intestinal epithelial growth and differentiation.

Patients with celiac disease have a pathological reaction to gluten and have either HLA-DQ2+ (90%) or HLA-DQ8+, but expression of these MHC class II haplotypes is not sufficient and other factors are necessary for the development of celiac sprue.

An increasing number of cancer patients are now receiving immune checkpoint inhibitors (ICIs), which boost the immune system to attack cancer cells.